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Abstract: A large body of evidence has linked unhealthy eating patterns with an alarming increase in
obesity and chronic disease worldwide. However, existing methods of assessing dietary intake in
nutritional epidemiology rely on food frequency questionnaires or dietary records that are prone to
bias and selective reporting. Herein, metabolic phenotyping was performed on 42 healthy participants
from the Diet and Gene Intervention (DIGEST) pilot study, a parallel two-arm randomized clinical
trial that provided complete diets to all participants. Matching single-spot urine and fasting plasma
specimens were collected at baseline, and then following two weeks of either a Prudent or Western
diet with a weight-maintaining menu plan designed by a dietician. Targeted and nontargeted
metabolite profiling was conducted using three complementary analytical platforms, where 80 plasma
metabolites and 84 creatinine-normalized urinary metabolites were reliably measured (CV < 30%)
in the majority of participants (>75%) after implementing a rigorous data workflow for metabolite
authentication with stringent quality control. We classified a panel of metabolites with distinctive
trajectories following two weeks of food provisions when using complementary univariate and
multivariate statistical models. Unknown metabolites associated with contrasting dietary patterns
were identified with high-resolution MS/MS, as well as co-elution after spiking with authentic
standards if available. Overall, 3-methylhistidine and proline betaine concentrations increased in
both plasma and urine samples after participants were assigned a Prudent diet (q < 0.05) with a
corresponding decrease in the Western diet group. Similarly, creatinine-normalized urinary imidazole
propionate, hydroxypipecolic acid, dihydroxybenzoic acid, and enterolactone glucuronide, as well
as plasma ketoleucine and ketovaline increased with a Prudent diet (p < 0.05) after adjustments for
age, sex, and BMI. In contrast, plasma myristic acid, linoelaidic acid, linoleic acid, α-linoleic acid,
pentadecanoic acid, alanine, proline, carnitine, and deoxycarnitine, as well as urinary acesulfame
K increased among participants following a Western diet. Most metabolites were also correlated
(r > ± 0.30, p < 0.05) to changes in the average intake of specific nutrients from self-reported diet
records reflecting good adherence to assigned food provisions. Our study revealed robust biomarkers
sensitive to short-term changes in habitual diet, which is needed for accurate monitoring of healthy
Nutrients 2019, 11, 2407; doi:10.3390/nu11102407 www.mdpi.com/journal/nutrients
Nutrients 2019, 11, 2407 2 of 30
eating patterns in free-living populations, and evidence-based public health policies for chronic
disease prevention.
Keywords: metabolomics; metabolite profiling; Prudent diet; Western diet; food provisions;
diet records; nutritional epidemiology; mass spectrometry
1. Introduction
A global epidemic of obesity and chronic non-communicable diseases threaten to reduce life
expectancy and impose a severe burden on public health [1,2]. Diet and lifestyle are two key modifiable
determinants of human health of particular importance for risk of cardiovascular disease (CVD),
type 2 diabetes, and some cancers [3]. CVD remains the leading cause of death globally [4], which has
been associated with a Western diet. Contemporary Western diets rich in trans fats, processed foods,
and red meat, including regular consumption of sweetened beverages and high glycemic index foods
lacking adequate fiber, have been strongly linked to chronic inflammation, and metabolic syndrome [5].
These deleterious eating patterns increasingly impact cardiometabolic health across the lifespan [6].
In contrast, a Prudent diet and analogous health-promoting diets (e.g., DASH, Mediterranean, Nordic)
that include a greater intake of fruits and vegetables, lean meats, and whole grains, reduce blood lipids,
improve blood sugar homeostasis, and lower blood pressure [7,8]. However, there is an urgent need
for more accurate dietary assessment tools for the validation of nutritional policies that are effective for
chronic disease prevention on a population level, unlike the traditional diet-heart hypothesis [9].
Nutritional epidemiologists face unique challenges in light of the highly complex chemical
composition of foods, whose physiological effects are often confounded by interactions of diet with
genes, lifestyle, microbiome, and other environmental exposures [10]. To date, observational studies
in nutrition mainly rely on self-reported measures of dietary intake, including methods of recall
(e.g., food frequency questionnaires, 24 h dietary recall) or real-time recording (e.g., food diaries) that
are prone to bias and selective reporting [11]. Alternatively, targeted assays exist for measuring energy
expenditure (e.g., doubly-labeled water), as well as specific macronutrients (e.g., protein), electrolytes
(e.g., sodium) and micronutrients (e.g., vitamin D) with established reference ranges associated with
nutritional status and/or chronic disease risk. However, these methods are not routinely applied in
large-scale human studies due to major cost barriers while representing only a small fraction of total
food exposures [12,13]. In this context, new advances in high throughput metabolomics offer a holistic
approach for measuring complex dietary patterns in lieu of specific nutrients in human biofluids,
such as blood and urine [14]. Recent metabolomic studies have identified dietary biomarkers [15,16] to
monitor for dietary adherence, as well as validate or correct standard dietary assessment methods used
in nutritional epidemiology [17–21]. However, few dietary biomarkers are unique to specific foods,
nor adequately validated as quantitative measures of recent, or habitual food intake in well-controlled
randomized clinical trials [22–24].
Herein, metabolic phenotyping of matching plasma and urine specimens were analyzed from
healthy participants from the Diet and Gene Intervention Study (DIGEST), which was a randomized
controlled trial to explore the short-term effects of a Prudent diet on CVD risk factors, where individuals
were provided all foods to prepare at home [25]. A modest reduction in systolic and diastolic blood
pressure, and total cholesterol was reported for participants following a Prudent diet after two weeks as
compared to a Western diet; however, dietary adherence relied on participant self-reporting, and food
preparation methods were not standardized likely contributing to variability in treatment responses [25].
In this work, we sought to identify specific metabolic trajectories in plasma and urine that may serve
as responsive biomarkers reflecting short-term changes in habitual diet, which were measured in
free-living individuals outside of a dedicated metabolic ward or hospital stay. These dietary biomarkers
not only confirmed good adherence to assigned food provisions, but were also associated with healthy
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eating patterns indicative of a Prudent diet [26], as compared to a Western diet that increases overall
risk for CVD [27].
2. Experimental
2.1. Study Design, Participant Eligibility and Dietary Self-reporting
DIGEST was a two-arm, parallel unblinded study to compare the effects of two weeks of a Prudent
diet as compared to a Western diet on CVD risk factors, and gene expression. Healthy participants
were recruited using flyers, and self-referral methods from McMaster University and the surrounding
areas. Exclusion criteria were an unwillingness to eat an assigned diet, or serious disease or illness,
including cardiometabolic and neurodegenerative disorders, with the full cohort selection criteria
described elsewhere [25]. A subset of 42 participants from DIGEST with paired urine and serum
samples available were selected for targeted and nontargeted metabolomics using three complementary
instrumental platforms, where participants had also completed self-reported dietary records at baseline,
and each week for two weeks following assigned food provisions. All participants from DIGEST picked
up their food allotment each week at the grocery store, during clinic visits, or food provisions were
delivered to their home by volunteers [25]. No detailed information was collected on food preparation
methods at home involving non-packaged foods; however all participants were requested to maintain
their normal lifestyle habits during the intervention period (e.g., physical activity, cooking methods).
A Harris-Benedict equation plus an activity factor was used to estimate participant’s energy intake,
compared this against their 7-day diet record, and assigned the appropriate diet plan at one of nine
energy levels (from 1600 through 3200 kcal) designed to maintain weight during the study period.
After the first week of intervention, participants were re-weighed and the food for the second week
was maintained, increased or decreased (using groups of 100 kcal snacks designed for each diet) as
necessary to maintain baseline weight. In order to maximize treatment effects in this short-term pilot
study, participants were assigned into two parallel arms of contrasting diets, namely a Western diet
reflecting a typical Canadian macronutrient profile with higher intake of processed foods (e.g., burgers,
fried chicken, cereals, processed cheeses), and a Prudent diet based around minimally processed foods
of lean protein (e.g., poultry, fish, legumes), whole grains, and a high amount of fresh fruits and
vegetables [25].
Briefly, one week prior to beginning the intervention diet, all DIGEST participants attended
a pre-study visit, where they were instructed by staff on how to complete a prospective 7-day
food diary. An instruction sheet and booklet were also provided. Participants were provided
with a blank diary and asked to record each item consumed at each eating occasion (e.g., food
name, amount, method of cooking). Common household measures were used for food and drink
(e.g., cups, tablespoons). For composite foods that could not be readily split, such as a fruit pie or
meat casserole, participants were asked to provide recipe details. Foods eaten away from home
were recorded in as much detail as possible (e.g., restaurant name, item). Study staff reviewed the
food diary with each participant on the day of the baseline visit. At the beginning of each week of
the intervention period, each participant was provided with a 7-day meal plan that listed the exact
food items and quantities they were to eat. As each food was eaten, participants were instructed
to check that item off the list. Participants also recorded any additional items consumed that were
not on the checklist. This checklist was returned at the end of each of the two weeks during the
intervention, and study staff reviewed this with each participant. The pre-study diets were entered
into, and analyzed using The Food Processor® (ESHA Research Inc., Salem, OR, USA) for micro-
and macronutrients, and servings of fruits and vegetables. A diet quality index score was assigned
for each participant at baseline, and an average over the two week intervention period as follows;
one “Prudent” point was assigned for each of the following criteria: polysaturated:saturated fat
ratio (poly:sat) > 1.0, saturated fat < 7%, total fiber > 28 g/day, fruits + vegetables > 5 servings/day,
and potassium > 3500 mg/day. The maximum score was 5. Similarly, one "Western" point was
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assigned for each of the following criteria: poly:sat < 0.5, saturated fat > 16%, total fiber < 9 g/day,
fruits + vegetables < 5 servings/day, and potassium < 3500 mg/day. The maximum score was 5.
DIGEST participants were classified as "predominantly" Prudent if the Prudent score minus the
Western score was ≥ 2, or they were classified as "predominantly" Western if the Western score
minus the Prudent score was ≥ 2; however, based on these criteria, few participants had Prudent diet
characteristics (14%; 6 out of 42) with most having Western eating habits at baseline (86%, 36 out of 42).
Dietary adherence was a measure of the % of the prescribed foods that they reported eating based on
the foods they checked-off from a menu list that they consumed, which was > 95% for both treatment
arms. A total of 20 micro- and macronutrient categories (from over 120) from self-reporting dietary
records were different (q < 0.05; Bonferroni adjustment) between assigned Prudent and Western diets
among DIGEST participants, which were subsequently correlated with top-ranked plasma and urinary
metabolites when classifying putative biomarkers of contrasting diets.
2.2. Chemicals and Reagents
Ultra HPLC grade LC-MS solvents (water, methanol, acetonitrile) obtained from Caledon
Laboratories Ltd. (Georgetown, ON, Canada) were used to prepare all buffer and sheath liquid
solutions. Proline betaine was purchased from Toronto Research Chemicals Inc. (Toronto, ON, Canada).
All other chemicals were obtained from Sigma-Aldrich Inc. (St. Louis, MO, USA).
2.3. Nontargeted Metabolite Profiling of Plasma and Urine by MSI-CE-MS
Fasting plasma (EDTA) samples together with matching single-spot urine samples were collected
from all DIGEST participants during clinic visits on day 1 and day 14, which were then stored at
−80 ◦C [25]. Multisegment injection-capillary electrophoresis-mass spectrometry (MSI-CE-MS) was the
major platform used for nontargeted profiling of polar/ionic metabolites from both plasma and urine
samples [28], which was performed on an Agilent G7100A CE (Agilent Technologies Inc., Mississauga,
ON, Canada) equipped with a coaxial sheath liquid (Dual AJS) Jetstream electrospray ion source
coupled to an Agilent 6230 TOF-MS system. All separations used uncoated fused-silica capillaries
(Polymicro Technologies Inc., Phoenix, AZ, USA) with a total length of 120 cm and an inner diameter
of 50 µm. About 7 mm of polyimide coating was removed from both distal ends to avoid sample
carry-over and prevent polyimide swelling from contact with organic solvent [29]. The background
electrolyte (BGE) consisted of 1 M formic acid with 15% volume acetonitrile (pH 1.8) under positive
ion mode, and 50 mM ammonium bicarbonate (pH 8.5) under negative ion mode for characterization
of the ionic metabolome, including cationic and anionic metabolites from matching plasma and urine
specimens, respectively. All CE separations were performed under normal polarity with an applied
voltage of 30 kV at 25 ◦C. However, a pressure gradient of 2 mbar/min from 0 to 40 min was used
for MSI-CE-MS analyses under negative ion mode conditions to shorten analysis times for highly
charged anionic metabolites (e.g., citrate). The TOF-MS system was operated with full-scan data
acquisition over a mass range of m/z 50-1700 and an acquisition rate of 500 ms/spectrum. The sheath
liquid was comprised of 60% volume MeOH with 0.1% volume formic acid for positive ion mode,
and 50% volume MeOH for negative ion mode. The ESI conditions were Vcap = 2000 V, nozzle voltage
= 2000 V, nebulizer gas = 10 psi, sheath gas = 3.5 L/min at 195 ◦C, drying gas 8 L/min at 300 ◦C, and the
MS voltage settings were fragmentor = 120 V, skimmer = 65 V and Oct1 RF = 750 V.
Thawed plasma (50 µL) on ice was diluted four-fold with deionized water containing 20 µM
3-chloro-L-tyrosine (Cl-Tyr), 20 µM 4-fluoro-L-phenylalanine (F-Phe), and 20 µM naphthalene
monosulfonic acid (NMS) as internal/recovery standards. Diluted plasma samples were vortexed
for 30 s and then plasma protein was filtered via ultracentrifugation using a 3 kDa MWCO Nanosep
centrifugal device (Pall Life Sciences, Port Washington, NY, USA) at 14,000 g for 15 min prior to analysis.
All filters were initially pre-washed in deionized water prior to plasma addition. Frozen urine was
thawed slowly on ice, vortexed for 30 s, and particulate matter was sedimented by centrifugation at
14,000 g for 5 min. All urine samples were then diluted five-fold in deionized water containing Cl-Tyr,
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F-Phe and NMS as internal/recovery standards (20 µM). A seven sample serial injection format was
used in MSI-CE-MS [30–32] consisting of a serial injection of six individual plasma filtrate or urine
samples together with a pooled quality control (QC) within each experimental run; the latter sample
was used to assess technical variance while also allowing for robust batch correction due to long-term
signal drift in ESI-MS [31,33]. Multiplexed electrophoretic separations in MSI-CE-MS was performed
by programming a hydrodynamic injection sequence with each sample (5 s at 100 mbar) alternating
with a BGE spacer (40 s at 100 mbar) prior to voltage application as described elsewhere [30–32].
Nontargeted metabolite profiling of plasma or urine specimens by MSI-CE-MS was conducted by
pairing together matching baseline and post-treatment samples from three DIGEST participants
together with a QC in a randomized injection position for each run. Different serial sample injection
configurations in MSI-CE-MS were also applied for rigorous authentication of metabolites using a
dilution trend filter, as well as the acquisition of calibration curves for metabolite quantification [30–32].
Briefly, authentic metabolites were defined by their unique accurate mass, and relative migration time
(m/z:RMT) under positive (+) or negative (−) ion mode detection, after filtering out spurious signals,
background ions, redundant adducts, in-source fragments, and isotopic features that comprise the
majority of signals in MS-based metabolomics [33]. Additionally, only frequently detected plasma
or urinary metabolites measured in the majority of samples from DIGEST participants (> 75%) with
acceptable technical precision based on repeated analysis of QC samples (mean CV < 30%) were included
in the final data matrix as a way to reduce false discoveries and data over-fitting [34]. Missing (i.e., zero)
data below method detection limits were replaced with a minimum value corresponding to half of the
lowest response measured for a given metabolite in all samples analyzed. Overall, 70 and 50 authentic
polar/ionic metabolites were measured consistently in the majority of urine and plasma samples
by MSI-CE-MS, respectively including unknown ions, and recovery standards that fully satisfied
our multi-level metabolomics selection criteria, and rigorous filtering procedure. Also, creatinine
concentrations were measured by MSI-CE-MS, which were used to reduce biological variance and
correct for differences in hydration status for single-spot urine samples analyzed in this study.
2.4. Unknown Metabolite Identification by MS/MS
High-resolution tandem mass spectrometry (MS/MS) was employed for structural elucidation
of unknown metabolites of biological significance from pooled QC samples prepared in this study.
Collisional–induced dissociation (CID) experiments were performed on an Agilent G7100A CE system
with a coaxial sheath liquid Jetstream electrospray ion source connected to an Agilent 6500 iFunnel
QTOF instrument. Metabolite identification in this work adopted reporting standards recommended
from the Metabolomics Standards Initiative [35], including unambiguous identification (level 1) that
was confirmed with matching MS/MS spectra, and co-migration with an authentic standard acquired
on the same instrument. Additionally, tentative/probable identification (level 2) was achieved by
comparison of MS/MS spectra from public databases or published literature, or partial annotation of
MS/MS spectra guided by in silico software tools with metabolite class (level 3). Otherwise, compounds
with unknown chemical structures were characterized by their most likely molecular formula (level 4);
the latter case typically occurred for low abundance metabolites that had inadequate responses for
their precursor ion when using MS/MS. Also, the electromigration behavior of polar/ionic metabolites
(i.e., RMT) provided useful qualitative information that complemented MS/MS when selecting among
several isobaric or isomeric candidate ions. MS/MS spectra were acquired from pooled plasma or
urine samples that were injected hydrodynamically using a conventional single sample injection plug
at 50 mbar for 10 s followed by 5 s with BGE. Precursor ions were selected for CID experiments
at different collision energies (e.g., 10, 15, 20 or 40 V). Mirror plots depicting MS/MS spectra for
unknown metabolites in pooled samples were acquired under an optimal collision energy, and then
compared to their respective authentic reference standard (if available) under the same experimental
conditions, which were generated using the “InterpretMSSpectrum” R Package. Otherwise, MS/MS
spectra were annotated based on their characteristic product ions, and neutral mass losses for de
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novo structural elucidation (level 2 or 3), which was guided by in silico MS/MS spectra generated
by CFM-ID [36]. Whenever possible, experimental MS/MS spectra were also compared to entries
from curated/open-access public repositories (HMDB, http://www.hmdb.ca), or published in literature.
The exact stereochemistry was uncertain for a subset of dietary biomarkers in plasma or urine if
authentic standards were lacking. MS/MS spectra for five urinary metabolites associated with a Prudent
diet in this work were also deposited onto HMDB.
2.5. Total Plasma Fatty Acid Determination by GC-MS
A GC-MS method was used for targeted analysis of 26 total (hydrolyzed) fatty acids (FA)
and their isomers from plasma extracts on an Agilent 6890 GC coupled to an Agilent 5973 single
quadrupole mass spectrometer with electron impact ionization (EI) with minor modifications [37].
Total hydrolyzed plasma FA were analyzed by GC-MS as their methyl ester derivatives (FAME)
using N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) (≥98.5%). Isotopically-labeled myristic
acid-d27 (98%), stearic acid-d35 (98%) and pyrene-d10 (98%) were obtained from Cambridge
Isotope Laboratories (Tewksbury, MA, USA). HPLC grade chloroform (≥99.5%), methanol (99.8%),
hexanes (≥99.5%) and Ultra LC-MS grade water were purchased from Caledon Laboratories Ltd.
(Georgetown, ON, Canada). The antioxidant, butylated hydroxytoluene (BHT, 490 µL) was added
to all FA calibrant solutions prepared in methanol to prevent autooxidation. Briefly, a 10 µL aliquot
of thawed plasma was mixed with 5 µL of a 1.0 mg/mL C18:0-d35 recovery standard. Concentrated
sulfuric acid (10 µL) was added as a transesterification catalyst and vortexed for 2 min before incubation
for 4 h at 80 ◦C to produce FAME for improved volatility. Cooled samples were then mixed with
500 µL of 9 g/L NaCl and 200 µL hexanes and vortexed for 2 min prior to centrifugation at 1400 g
at 4 ◦C for 5 min. GC inserts were prepared with 45 µL of hexane supernatant with 5 µL of internal
standard pyrene-d10 and vortexed for 2 min before injection. Total plasma FAME were resolved on a
Supleco SP-2380 column (30 m × 0.25 mm × 0.20 µm) using an optimal temperature program within
30 min. Samples were injected in 1.0 µL volumes using a splitless injector held at 250 ◦C, the carrier
gas was helium at 1.0 mL/min and the transfer line was held at 270 ◦C. Pooled QC and blank extracts
were analyzed together with each batch of 8 to 10 randomized plasma samples when using GC-MS
in order to assess technical precision and monitor for background contamination. A temperature
program used for resolution of major FAME from plasma hydrolysates comprised of a temperature
gradient of 20 ◦C/min starting from 2 min at 80 ◦C until 20 min at 160 ◦C, which was further increased
to 190 ◦C for 3 min prior to elution at 300 ◦C for 5 min with a total run time of 28 min. In most cases,
FAME were quantified in GC-MS based on the integration of the relative response ratio of their [M-15]+
fragment ion relative to pyrene-d10 as internal standard when using single ion monitoring (SIM) mode
detection. Calibrations curves from FAME standards were used for FA quantification, as well as their
identification when comparing their characteristic EI-MS spectra (70 eV) and elution times.
2.6. Targeted Urinary Electrolyte Analysis
Targeted analysis of 8 inorganic/involatile electrolytes in urine was performed using two
complementary CE-UV methods adapted from Nori de Macedo et al. [38] and Saoi et al. [32] for
anionic (e.g., iodide) and cationic (e.g., sodium) electrolytes, respectively. First, analysis of major
cationic electrolytes was performed on frozen urine samples that were thawed, vortexed for 30 s and
centrifuged at 14,000 g for 5 min. An aliquot of the urine supernatant was diluted five-fold with
deionized water containing 0.5 mM lithium as an internal standard. Samples were analyzed on an
Agilent G7100A CE system with UV photodiode array detection with indirect absorbance detection
at 214 nm. All samples were injected hydrodynamically for 10 s (at 35 mbar) and separation was
performed under normal polarity at 30 kV at 25 ◦C using a 50 µm inner diameter capillary with 60 cm
total length. The background electrolyte (BGE) was 5 mM formic acid containing 12.5 mM creatinine,
and 4 mM 18-crown-6 ether at pH 4.0 (adjusted with 1 M sulfuric acid). In this case, ammonium
(NH4+), sodium (Na+), potassium (K+), calcium (Ca2+), and magnesium (Mg2+) were analyzed in
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urine samples [32]. Additionally, all urine samples were analyzed using a complementary CE assay for
UV-absorbing inorganic anions, including nitrate (NO3−), iodide (I−), and thiocyanate (SCN−) [38].
In this case, the BGE was comprised of 180 mM lithium hydroxide, 180 mM phosphoric acid, and 10 mM
α-cyclodextrin (α-CD) at pH 3 (adjusted with 1 M phosphoric acid), where 1,5-naphthalene disulfonic
acid (NDS) was used as an internal standard. Samples were injected hydrodynamically for 80 s at
0.5 psi and analyzed at 25 ◦C under a reversed polarity at −18 kV with UV absorbance detection at
226 nm (288 nm for NDS). In both CE-UV assays, a pooled QC was measured intermittently after every
batch of six urine samples.
2.7. Data Preprocessing and Statistical Analysis
All MSI-CE-MS data were integrated and analyzed using Agilent MassHunter Qualitative
Analysis B.07.00 and Microsoft Excel and Igor (Wavemetrics Inc., Lake Oswego, OR, USA). In all cases,
the integrated ion response (i.e., peak area) for each metabolite was normalized to an internal standard,
Cl-Tyr migrating from the same sample by MSI-CE-MS, whereas F-Phe was used as a recovery standard
to monitor for long-term technical precision in control charts. Also, a batch-correction algorithm
was applied to creatinine-normalized urine metabolomic data to adjust for long-term signal drift
in ESI-MS during data acquisition as outlined in a recent work [31]. This algorithm is based on an
empirical Bayesian framework [39], which takes advantage of QC samples included in each serial
injection run when using MSI-CE-MS, including batch order and injection sequence information.
However, the batch-correction did not provide any significant improvement in the overall technical
precision of plasma metabolome data and thus was not applied in this case. All non-batch (plasma) and
batch-corrected (creatinine normalized urine) metabolomic data was pre-processed using generalized
log-transformation, and autoscaling prior to multivariate statistical analysis using MetaboAnalyst
4.0 (www.metaboanalyst.ca) [40], including volcano plots, principal component analysis (PCA),
hierarchical cluster analysis (HCA)/2D heat maps, receiver operating characteristic (ROC) curves,
orthogonal partial least squares-discriminant analysis (OPLS-DA), as well as multivariate empirical
Bayes analysis (MEBA) of variance; the latter method is optimal for analyzing time-series data [41]
relevant to identifying metabolic trajectories reflective of contrasting diets. To validate each OPLS-DA
model, cross-validation and permutation testing (n = 1000) on paired metabolome data sets (i.e., ratio
of metabolite response based on assigned diet relative to baseline diet for each subject) following
glog transformation and autoscaling, whereas Hotelling’s T-squared distribution using MEBA was
performed on glog-transformed metabolomic time series data for DIGEST participants at baseline and
following 2 weeks of food provisions. These complementary statistical approaches were used for
unsupervised data exploration to inspect overall trends in reduced dimensionality, as well as supervised
data analysis for ranking metabolites modulated by contrasting diets without adjustments for covariates.
Additionally, normality tests, partial Pearson correlation analysis, and mixed model ANOVA were
performed on top-ranked dietary biomarker candidates using the Statistical Package for the Social
Sciences (SPSS, version 18.0). In this case, a partial listwise Pearson correlation analysis of lead plasma
and creatinine-normalized metabolite responses to 20 major nutrient categories from self-reported
food records from DIGEST participants (n = 42) were adjusted for age, sex, and post-intervention BMI.
Only metabolites that had a correlation coefficient of r > ±0.300 and p < 0.05 for 2 or more nutrient
categories were considered as significant in this work. A repeat measures general linear mixed ANOVA
model was also performed with the number of levels set at 2 for the repeat sampling (i.e., time; baseline
diet, and two weeks after assigned diet) while setting the intervention diet (i.e., treatment arm; P-W,
and W-P) as the between-subject factor with age, sex, and post-intervention BMI as potential covariates.
Overall, plasma and urine metabolites that satisfied MEBA and/or mixed ANOVA models, as well as
partial correlation analysis to more than two nutrient categories from diet records were defined as
robust dietary biomarkers in our study.
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3. Results
3.1. Study Design, Baseline Habitual Diet and Metabolomics Workflow
The DIGEST pilot study was a two-arm parallel dietary intervention involving
healthy/non-smoking participants recruited from the local community as described elsewhere [25].
A CONCERT diagram summarizes eligibility criteria (Figure S1), where all participants completed
a seven-day diet record and then were randomly allocated to eat a weight-maintaining Prudent or
Western diet over two weeks. Participants (n = 42) with contrasting habitual diets were selected in
this unblinded metabolomics study based on the availability of matching plasma and urine samples
with complete diet records as depicted in Figure 1A. There were more women (64%) recruited than
men, however there were no differences in age (mean age of 47 years ranging from 20 to 69 years),
body composition (mean BMI of 27 kg/m2 with 26% defined as obese) and average caloric intake
(mean of 1940 kcal/day) between assigned diet groups, and most participants were Caucasian (78%)
with no self-identified tobacco smokers (Table S1). Also, no differences in baseline blood lipids,
fasting glucose, inflammatory biomarkers, and blood pressure were evident between the two treatment
arms. Since Prudent diet scores (<2) were low for this cohort overall (Table S1), 18 participants were
classified as having a “Prudent-like” diet at baseline, but this was due to their lower average Western
diet score (2.61 ± 0.69); this sub-group was randomized to an assigned Western diet (referred to as
P-W) in this study. In contrast, 24 participants, having a predominate Western diet at baseline due to
their higher average Western diet score (3.42 ± 0.93), were randomized to a Prudent diet (referred to as
W-P). Importantly, there were no major differences in plasma or urine metabolic phenotypes measured
at baseline, reflecting similar habitual dietary patterns for DIGEST participants in both treatment arms.
Figure 1B,C depict 2D heat maps for matching plasma and urine metabolomes measured from
DIGEST participants (n = 42) at baseline and following two weeks of assigned food provisions. A total
of 80 serum metabolites and 84 urinary metabolites were reliably measured (CV < 30%) in the majority
of participants (> 75%) when using a validated data workflow for non-targeted metabolite profiling
with stringent QC [30–32]. A rigorous approach to metabolite authentication was implemented to
reject spurious, redundant, and background ions that comprise the majority of molecular features
detected in ESI-MS [33] in order to reduce false discoveries in metabolomics [34]. Overall, three
orthogonal instrumental platforms were used to characterize polar/ionic metabolites from plasma
and urine using MSI-CE-MS, as well as total (hydrolyzed) plasma fatty acids (FA) by GC-MS, and
inorganic urinary electrolytes by CE with UV detection (Figure S2). Also, 2D scores plots from principal
component analysis (PCA) of plasma and creatinine-normalized urine metabolome demonstrated
good technical precision from pooled samples used as QC (median CV = 4%–12%) as compared to
the biological variance from random/single-spot urine (median CV = 65%–78%) and fasting plasma
(median CV = 32%–53%) metabolomes (Figure S3). A batch-correction algorithm was also applied
to urine metabolome data to minimize signal drift when using MSI-CE-MS [31], where each run is
comprised a serial injection of six individual samples together with a QC. Also, control charts for the
recovery standard (F-Phe) provide further evidence of acceptable precision (mean CV < 9%) with
few outliers exceeding confidence intervals (Figure S3). A complete list of authenticated metabolites
(Table S2) is annotated by their accurate mass and relative migration time (m/z:RMT) under positive (+)
or negative (−) ion mode detection, as well as their most likely molecular formula, mass error, level
of identification, and compound name. Unambiguous identification of metabolites associated with
contrasting diets was performed by spiking with authentic standards (if available) in conjunction with
high-resolution MS/MS, which were compared to reference spectra deposited in public data bases
(HMDB); otherwise, spectral annotation was guided by in silico fragmentation [36] using recommended
reporting standards for metabolite identification [35,42]. An overview of this metabolomics workflow
is outlined in Figure 2, which shows the detection of an unknown protonated molecule [M+H+] in
plasma, followed by its annotation using high-resolution MS, and subsequent identification (level 1) as
proline betaine (ProBet) using MS/MS after comparison to an authentic standard at the same optimum
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collision energy. Quantification of ProBet using an external calibration curve is also demonstrated, and
good technical precision (CV = 13%, n = 20) was achieved as shown in a control chart based on the
repeated analysis of a QC sample in every run throughout the entire study.
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Figure 2. Su ary of the etabolo ics data orkflow in MSI-CE-MS for the identification and
quantification of biomarkers associated with a Prudent or Western diet. (A) A total ion electropherogram
for plasma is shown with full-scan data acquisition under positive ion mode, whereas (B) an extracted ion
electropherogram for an authentic unknown cation (i.e., [M+H]+) is annotated by its m/z:RMT based on
serial injection of seven plasma samples within a single run. Each run is comprised three pairs of samples
collected from DIGEST participants (i.e., baseline diet, and two weeks after food provisions) together with
a QC for assessing technical precision, and correcting long-term signal drift. High-resolution MS spectra
allows for determination of the most likely molecular formula, and (C) MS/MS spectra enable structural
elucidation of the ion when compared to an authentic standard for ProBet. (D) Quantification of ProBet
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by MSI-CE-MS. (E) A control chart for ProBet from repeated m asurements of QC samples in every
MSI-CE-MS run demo strates acceptable technical precision (CV = 13%, n = 20) over 3 days of analysis.
3.2. Changes in Dietary Intake and Biomarker Classification
Major changes in self-reported dietary patterns were evident after two weeks of assigned diets
as summarized in Table 1. Although here were o significant changes in BMI o av rage caloric
intake between the two tr atment arms, greater palatability and atiety was pr viously reported for
DIGEST participants assigned to a Prudent diet [25]. As expected, the Prudent diet sub-group (W-P)
reported a higher daily intake of dietary fiber (total, insoluble, soluble), major electrolytes (K+, Mg2+),
fruits and/or vegetables, vitamins (A, C, and E), poly:sat, protein, and sugar or total carbohydrates.
In contrast, the Western diet sub-group (P-W) had a higher daily intake of fat (total, saturated, and trans),
sodium (Na+), and cholesterol. Figure S4 illustrates the relationship among 20 nutrient categories
reflecting contrasting diets when using PCA along with a hierarchical cluster analysis (HCA) with
2D heat map. There was strong co-linearity (r > ± 0.70) among most nutrient categories with two
distinctive clusters reflecting opposing Prudent and Western eating patterns.
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Table 1. Major changes in dietary patterns following two weeks of a Prudent or Western diet relative to baseline habitual diet of DIGEST participants (n = 42) based on
self-reported diet records.
Diet Category a W-P, n = 24 P-W, n = 18 p for Comparison/Outcome b
∆ Insoluble fiber intake (g/2000 kcal) (14.0 ± 5.3) (−5.0 ± 3.5) p = 1.4 × 10−15; Greater insol. fiber intake in Prudent arm
∆ Mg intake (mg/2000 kcal) (189 ± 89) (−134 ± 70) p = 3.5 × 10−15; Greater Mg intake in Prudent arm
∆ Fruits + vegetables intake
(servings/2000 kcal/day) (3.6 ± 1.4) (−1.8 ± 1.3) p = 7.3 × 10−15; Greater fruits + vegetables intake in Prudent arm
∆ Total fiber intake (g/2000 kcal) (16.6 ± 8.4) (−13.4 ± 8.1) p = 5.2 × 10−14; Greater total fiber intake in Prudent arm
∆ Energy from sat. fat (%) (−5.4 ± 3.2) (4.6 ± 2.4) p = 1.8 × 10−13; Greater intake of sat. fat in Western arm
∆ K intake (mg/2000 kcal) (1338 ± 617) (−854 ± 667) p = 2.5 × 10−13; Greater K intake in Prudent arm
∆ Vegetable intake (cup eq./2000 kcal) (1.8 ± 0.80) (−0.91 ± 0.92) p = 2.4 × 10−12; Greater K intake in Prudent arm
∆ Vitamin E (mg/2000 kcal) (7.7 ± 5.3) (−7.0 ± 4.0) p = 5.1 × 10−12; Higher intake of vitamin E in Prudent arm
∆ Poly:sat (ratio) (0.47 ± 0.21) (−0.14 ± 0.18) p = 8.2 × 10−12; Greater intake of Poly:sat in Prudent arm
∆ Vitamin C (mg/2000 kcal) (149 ± 69) (−40 ± 54) p = 1.2 × 10−11; Higher intake of vitamin C in Prudent arm
∆ Soluble fiber intake (g/2000 kcal) (3.9 ± 2.1) (−1.5 ± 1.5) p = 2.3 × 10−11; Greater total fiber intake in Prudent arm
∆ Fruit intake (cup eq./2000 kcal) (1.79 ± 0.93) (−0.92 ± 0.99) p = 5.9 × 10−11; Greater fruits intake in Prudent arm
∆ Energy from fat (%) (−7.5 ± 5.6) (5.6 ± 5.6) p = 9.0 × 10−10; Greater intake of total fat in Western arm
∆ Na intake (mg/2000 kcal) (−694 ± 590) (754 ± 658) p = 6.4 × 10−9; Greater Na intake in Western arm
∆ Vitamin A (µg/2000 kcal) (12,973 ± 56,344) (−7,847 ± 14,060) p = 1.4 × 10−7; Higher intake of vitamin A in Prudent arm
∆ Energy from sugar (%) (8.9 ± 5.4) (−1.5 ± 5.8) p = 7.3 × 10−7; Higher sugar intake in Prudent arm
∆ Energy from protein (%) (1.9 ± 3.6) (−3.2 ± 2.7) p = 1.5 × 10−5; Greater intake of protein in Prudent arm
∆ Energy from carbohydrates (%) (8.5 ± 7.8) (−0.35 ± 5.7) p = 2.9 × 10−4; Greater intake of total carbs in Prudent arm
∆ Cholesterol b (mg/2000 kcal) (−101 ± 140) (54 ± 110) p = 4.8 × 10−4; Greater intake of cholesterol in Western arm
∆ Energy from trans fat (%) (−0.26 ± 0.55) (0.27 ± 0.23) p = 6.4 × 10−4; Greater intake of trans fats in Western arm
a Mean daily differences (∆) in self-reported dietary patterns were evaluated from food records collected twice over a two week period at clinical visits as compared to the baseline habitual
diet of each participant. b There were no changes in measured total, LDL, and HDL cholesterol based on standard clinical blood measurements when using a two-tailed student’s t-test
with equal variance.
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Volcano plots (Figure S5) were initially used to evaluate changes in the metabolic phenotype
of participants using minimum cut-off thresholds (i.e., mean fold-change or FC > 1.3; p < 0.05).
Overall, contrasting diets generated pronounced changes in a wide range of plasma and urinary
metabolites that were largely absent for the same participants at baseline given modest differences
in their habitual diets prior to the start of food provisions (Table S1). For instance, 10 plasma
and 16 urinary metabolites were differentially expressed in W-P as compared to P-W diet groups,
including four metabolites satisfying a Benjamini-Hochberg/FDR adjustment (q < 0.05), including ProBet,
3- methylhistidine (Me-His), and two unknown urinary metabolites subsequently identified (level 2)
as hydroxypipecolic acid (OH-PCA), and imidazole propionic acid (ImPA). The identification and
quantification of Me-His were confirmed in both plasma and urine (Figure S6), whereas several unknown
urinary metabolites were tentatively identified (level 1 or 2) based on their characteristic MS/MS spectra,
such as OH-PCA (Figure S7), and acesulfame K (ASK; Figure S8). Similarly, targeted analysis of FAME
from hydrolyzed plasma extracts using GC-MS (Figure S9) allows for resolution of low abundance
trans isomers (linoelaidic acid, C18:2n-6trans), and saturated fatty acids (myristic acid, C14:0) from
abundant dietary fatty acids (linoleic acid, C18:2n-6cis). As expected, several circulating fatty acids
(Figure S5) were consistently elevated in circulation following a Western diet due to a higher average
consumption of total fats as compared to a Prudent diet.
3.3. Biomarkers of Contrasting Diets and Correlation with Diet Records
Complementary statistical methods that take advantage of the repeated-measures study design
were used to classify metabolites responses to contrasting dietary patterns. A paired orthogonal
partial least-squares discriminant analysis (OPLS-DA) model (Figure 3) was used to initially rank
metabolites in plasma and urine that were modulated by contrasting diets relative to each participant’s
baseline habitual diet (i.e., ion response ratio). Both OPLS-DA models demonstrated good accuracy
(R2 > 0.840) with adequate robustness (Q2 > 0.200) after permutation testing (p < 0.05, n = 1000).
S-plots confirmed that ProBet and Me-His were consistently elevated following a Prudent diet (W-P) in
both plasma and urine samples, whereas total plasma C14:0 and C18:2n-6cis had the most significant
increase following an assigned Western diet (P-W). Additionally, top-ranked creatinine-normalized
urinary metabolites excreted at higher levels following a Prudent diet included ImPA, OH-PCA,
dihydroxybenzoic acid (DHBA), enterolactone glucuronide (ETL-G), nitrate, and an unknown cation
(m/z 217.156, [M+H+]) tentatively identified as a dipeptide, valinyl-valine (Val-Val). In contrast, urinary
excretion of ASK was only modestly increased (p = 0.0686) following a Western diet. Additionally,
excellent discrimination among DIGEST participants following a Prudent or Western diet was achieved
when using top-ranked single or ratiometric biomarkers from a receiver operating characteristic (ROC)
curve (AUC > 0.820; p < 1.0 × 10−5) for plasma and creatinine-normalized urine samples (Figure S10).
For instance, plasma ProBet and the ratio of Me-His/C18:3n-6trans demonstrated good sensitivity and
specificity (≈ 80–90%) for classifying DIGEST participants based on their assigned diets similar to
urinary OH-PCA and the ratio of OH-PCA/Na+. A multivariate empirical Bayes analysis of variance
(MEBA) [41] was also used to characterize time-dependent metabolite profiles related to contrasting
diets after two weeks of food provisions. In this case, metabolic trajectories with distinctive time-course
profiles following a Prudent or Western diet were ranked based on their Hotelling’s T2 distribution
as shown for plasma (Figure S11) and urine (Figure S12), which were consistent with metabolites
identified as dietary biomarkers from volcano plots, ROC curves, and OPLS-DA models.
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A mixed ANOVA model, and partial Pearson correlation analysis to self-reported diet records
(after adjustments for sex, age, and BMI) were next applied to further validate the relevance of dietary
biomarkers identified from multivariate statistical models. Table 2 highlights that ProBet and Me-His
were the most robust plasma metabolites associated with a Prudent diet that satisfied several statistical
parameters (T2, F-value, r, adjusted p-value). For instance, ProBet was positively associated (r ≈ 0.520,
p = 0.001) with self-reported mean daily intake of fruit (cup eq./2000 kcal), vitamin C (mg/2000 kcal),
and fruits and/or vegetable servings (servings/2000 kcal), as well as negatively associated with fat
intake (r > −0.530, p < 0.001), including trans and saturated fat (%energy). Me-His had strong positive
correlations (r = 0.530−0.570, p < 0.001) with average daily intake of protein (%energy), insoluble fiber
(g/2000 kcal), electrolytes (Mg2+, K+; mg/2000 kcal), as well as fruits and/or vegetables reflecting a
Prudent diet. Other plasma metabolites classified as dietary biomarkers of contrasting diets included,
two carnitines (e.g., carnitine, C0; deoxycarnitine, dC0), two amino acids (e.g., proline, Pro; alanine,
Ala), three ketone bodies/intermediates (e.g., ketoleucine; kLeu; ketovaline, kVal; 3-hydroxybutyric acid,
OH-BA), and several long-chain fatty acids (e.g., C14:0, C15:0, C18:2n-6trans, C18:3n-6cis, C18:2n-6cis).
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Table 2. Top-ranked plasma metabolites associated with contrasting diets by DIGEST participants (n = 42) when using time series MEBA, mixed ANOVA, and partial
correlation analysis.
Metabolite/ID Identifier T2 a F-value b p-value b R c p-value c Food Record d
Proline betaine
(ProBet)
HMDB04827
144.102:0.984 (+)
MSI-CE-MS
C7H13NO2
Level 1
24.6 8.7 0.007
−0.601
−0.544
−0.528
0.528
0.518
<0.001
<0.001
0.001
0.001
0.001
Change %fat
trans fat %energy
Sat. fat %energy
Fruits; Vitamin C
Fruits + Vegetables
3-Methylhistidine
(Me-His)
HMDB00479
170.092:0.664 (+)
MSI-CE-MS
C7H11N2O3
Level 1
24.9 14.0 0.001
0.573
0.561
0.553
0.546
0.534
<0.001
<0.001
<0.001
<0.001
0.001
Magnesium
Protein %energy
Insoluble Fiber
Potassium
Fiber; Fruits + Vegetables
Proline
(Pro)
HMDB00162
116.070:0.927 (+)
MSI-CE-MS
C5H9NO2
Level 1
14.6 5.9 0.020
0.495
−0.412
−0.378
−0.362
−0.359
0.002
0.010
0.019
0.026
0.027
trans fat %energy
Fruits + Vegetables
Vegetables
Fruits
Protein %energy
Carnitine
(C0)
HMDB00062
162.112:0.735 (+)
MSI-CE-MS
C7H15NO3
Level 1
12.2 8.9 0.005
−0.464
0.426
−0.404
−0.386
−0.368
0.003
0.008
0.012
0.017
0.023
Poly:sat
trans fat %energy
Fruits + Vegetables
Vitamin E
Vitamin C
Deoxycarnitine or
γ-Butyrobetaine
(dC0)
HMDB01161
146.128:0.700 (+)
MSI-CE-MS
C7H16NO2
Level 1
11.9 7.9 0.008
0.367
0.366
−0.352
0.340
−0.336
0.024
0.024
0.030
0.037
0.039
Change %fat
Cholesterol
Magnesium
Sodium
Poly:sat
Linoelaidic acid
(C18:2n-6trans)
HMDB06270
294/67.1:15.289
GC-MS
C18H32O2
Level 1
10.3 21.5 <0.001
−0.579
−0.555
−0.486
0.485
0.464
<0.001
<0.001
0.002
0.002
0.003
Poly:sat
Fruits + Vegetables
Vitamin C
Sat. fat %energy
trans fat %energy
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Table 2. Cont.
Metabolite/ID Identifier T2 a F-value b p-value b R c p-value c Food Record d
Pentadecanoic
acid
(C15:0)
HMDB000673
294/67.1:14.171
GC-MS
C18H32O2
Level 1
9.9 16.8 <0.001
−0.471
0.408
−0.403
−0.379
0.379
0.003
0.011
0.012
0.019
0.019
Poly:sat
Change %fat
Fruits + Vegetables
Vitamin A
Change %sat. fat
Alanine
(Ala)
HMDB00161
90.056:0.783 (+)
MSI-CE-MS
C3H7NO2
Level 1
9.6 6.2 0.018
0.452
0.439
0.428
−0.395
0.386
0.004
0.006
0.007
0.014
0.017
Change %sat. fat
Change %fat
trans fat %energy
Protein %energy
Sat. fat %energy
Ketoleucine or
4-Methyl-2-oxopentanoic
acid
(kLeu)
HMDB00695
129.056:1.209 (−)
MSI-CE-MS
C6H10O3
Level 1
7.7 4.4 0.043
0.493
−0.459
0.456
0.453
0.452
0.002
0.004
0.004
0.004
0.004
Fruits + Vegetables
Sat. fat %energy
Fruits
Poly:sat
Protein %energy
3-Hydroxybutyric
acid
(OH-BA)
HMDB00357
103.040:1.043 (−)
MSI-CE-MS
C4H8O3
Level 1
7.6 2.9 0.097
0.437
−0.429
0.425
0.419
0.415
0.006
0.007
0.008
0.009
0.01
Fruits
trans fat %energy
Poly:sat
Vitamin A
Fruits + Vegetables
α-Linoleic acid
(C18:3n-6cis)
HMDB001388
292/79.1:15.096
GC-MS
C18H30O2
Level 1
7.0 11.6 0.002
−0.441
−0.397
−0.391
0.391
−0.387
0.006
0.013
0.015
0.015
0.016
Poly:sat
Vitamin A
Fruits + Vegetables
trans fat %energy
Vitamin E
Ketovaline or
α-Isovaleric acid
(kVal)
HMDB00019
115.040:1.079 (−)
MSI-CE-MS
C5H8O3
Level 1
6.3 2.4 0.125
0.489
0.472
0.466
0.458
0.451
0.002
0.003
0.003
0.004
0.004
Protein %energy
Fiber (total)
Fruits + Vegetables
Vitamin E
Poly:sat
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Table 2. Cont.
Metabolite/ID Identifier T2 a F-value b p-value b R c p-value c Food Record d
Myristic acid
(14:0)
HMDB00826
242/74.1:10.336
GC-MS
C15H30O2
Level 1
5.0 15.2 <0.001
−0.535
−0.512
0.503
0.465
−0.463
0.001
0.001
0.001
0.003
0.009
Poly:sat
Fruits + Vegetables
Change %fat
Change %sat. fat
Vitamin A
Linoleic acid
(C18:2n-6cis)
HMDB000673
294/67.1:14.171
GC-MSC18H32O2
Level 1
2.6 16.4 <0.001
−0.438
0.420
0.412
−0.382
−0.370
0.006
0.009
0.005
0.018
0.022
Poly:sat
Change %fat
Change %sat. fat
Fruits + Vegetables
Vitamin A
a Hotelling’s T-squared distribution using MEBA on glog-transformed metabolomic time series data. b Mixed ANOVA model derived from within-subject (diet × time interaction,
p < 0.05) contrasts when adjusted for sex, age, and BMI. c Partial Pearson correlation of urinary metabolites to food records with listwise deletion when adjusted for sex, age, and BMI,
where r > ± 0.30 and p < 0.05. d Top five nutrient categories from self-reported food records that were significantly correlated to urinary metabolites following contrasting provisional diets.
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Overall, all total (hydrolyzed) plasma fatty acids were positively correlated to a Western diet
with a higher average intake of fats (trans fats, sat. fats), and a corresponding lower intake of fruits
and/or vegetables, poly:sat and micronutrients (vitamins A, C, and E). Similar outcomes were also
measured for plasma carnitines and amino acids, which were positively correlated to a Western diet.
In contrast, metabolic intermediates of branched-chain amino acids and energy metabolism, namely,
plasma kLeu, kVal and OH-BA, were positively associated with a Prudent diet, including higher
average intake of protein, fiber, fruits and/or vegetables, poly:sat, and vitamins. Table 2 summarizes
14 plasma metabolites that function as robust biomarkers of contrasting diets since they satisfied at
least two of the three statistical models (p < 0.05) following adjustment for covariates between groups
while also having a significant correlation (r > ± 0.3, p < 0.05) with at least two nutrient categories from
self-reported diet records. An analogous strategy was also used to identify 8 creatinine-normalized
urinary metabolites significantly associated with contrasting diets (Table 3). Urinary Me-His and
ProBet were among the top-ranked metabolites sensitive to short-term changes in habitual diet with
strong positive associations with a Prudent diet. Additionally, several other urinary metabolites were
excreted at higher levels for DIGEST participants following a Prudent diet, including OH-PCA and
ImPA. Furthermore, two plant-derived phenolic metabolites in urine, namely ETL-G and DHBA were
also correlated to healthy eating patterns, such as greater intake of fruits, vegetables and micronutrients.
However, creatinine-normalized Val-Val and DMG in urine were weakly correlated with only two
nutrient categories (p ≈ 0.05) from self-reported diet records. Interestingly, urinary ASK, nitrate and an
unidentified cation (m/z:RMT, 276.144:0.858, [M+H+]) were not correlated to any major nutrient from
self-reported diet records despite showing treatment responses to contrasting diets.
3.4. Metabolic Trajectories and Metabolite Correlation Analysis
Representative metabolic trajectories are depicted for top-ranked dietary biomarkers that were
measured in plasma (Figure S12) and urine (Figure S13) specimens from DIGEST participants. In all
cases, metabolic phenotype changes were evident following two weeks of food provisions with the
exception of urinary DHBA, which was the only compound different between assigned diet groups
at baseline (p = 0.00803). The majority of dietary biomarkers underwent an increase in response for
participants consuming a Prudent diet except for circulating fatty acids, two amino acids (Pro, Ala) and
two carnitines (C0, dC0) in plasma, which increased following a Western diet. Metabolic trajectory plots
also highlight considerable between-subject variances to assigned diets while also identifying outliers
among certain individuals due to potential dietary non-adherence and/or inaccurate self-reporting.
Figure 4 illustrates metabolic trajectory plots for ProBet and Me-His as they were among the most
sensitive biomarkers responsive to contrasting diets, and they were also measured consistently in
both plasma and urine samples. Scatter plots show the quantitative relationship between Me-His
and ProBet concentrations in plasma as compared to their excreted concentrations in urine with
the self-reported average daily intake of protein (%energy), and fruit servings (servings/2000 kcal),
respectively. For example, there was a 2.4-fold increase in mean plasma Me-His concentration following
two weeks of food provisions that corresponded to a 28% greater intake of dietary protein when
comparing Prudent (W-P, n = 24) and Western (P-W, n = 18) diet groups. Similar results were also evident
when comparing creatinine-normalized concentrations of Me-His in urine, which generated a 4.8-fold
higher mean concentration in the Prudent relative to Western diet treatment arm. Overall, there was a
strong correlation between Me-His concentrations and self-reported dietary protein intake (r = 0.430
to 0.560) with few exceptions, such as one participant (W-P, #19) who had consistently low Me-His
concentrations in both biofluids consistent with their self-reported protein intake that was characteristic
of the Western diet group (P-W); this outcome likely indicates non-adherence to their assigned diet.
In contrast, a second participant (P-W, #28) had higher Me-His concentrations in both plasma and urine
despite their low self-reported protein intake from diet records that was suggestive of a reporting bias.
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Table 3. Top-ranked creatinine-normalized metabolites associated with contrasting diets by DIGEST participants (n = 42) when using time series MEBA, mixed
ANOVA, and partial correlation analysis.
Metabolite/ID Identifier T2 a F-test b p-value b r c p-value c Food Record d
3-Methylhistidine
(Me-His)
HMDB00479
170.092:0.664 (+)
MSI-CE-MS
C7H11N2O3
Level 1
17.9 7.8 0.008
0.524
0.517
0.457
−0.432
0.431
0.001
0.001
0.004
0.007
0.007
Fiber (total)
Fruits + Vegetables
Vitamin E
trans fat %energy
Protein %energy
5-Hydroxypipecolic
acid
(OH-PCA) *
HMDB0029246
146.081:1.180 (+)
MSI-CE-MS
C6H11NO3
Level 2
16.3 1.1 0.293
−0.468
0.397
0.390
0.381
0.374
0.003
0.013
0.016
0.018
0.021
Change fat
Fiber (total)
Fruits + Vegetables
Vitamin E
Poly:sat
Imidazole
propionic acid
(ImPA)
HMDB02271
141.066:0.690 (+)
MSI-CE-MS
C6H8N2O2
Level 2
16.1 10.8 0.002
0.515
0.511
0.471
0.463
0.444
0.001
0.001
0.003
0.003
0.005
Fiber (total)
Fruits + Vegetables
Protein %energy
Vitamin E
Poly:sat
Proline betaine
(ProBet)
HMDB04827
144.099:0.984 (+)
MSI-CE-MS
C7H13NO2
Level 1
15.5 10.8 0.002
0.487
−0.487
0.482
0.480
0.469
0.002
0.002
0.002
0.002
0.003
Poly:sat
trans fat %energy
Fiber
Fruits + Vegetables
Fiber (insoluble)
Valinyl-valine
(Val-Val)
HMDB0029140
217.156:0.847 (+)
MSI-CE-MS
C10H20N2O3
Level 3
10.9 3.8 0.060 0.3200.320
0.050
0.050
Poly:sat
Vitamin E
Enterolactone
glucuronide
(ETL-G)
HMDB0240377
473.145:0.934 (−)
MSI-CE-MS
C24H25O10
Level 2
8.0 7.3 0.010
−0.434
0.387
0.340
0.332
0.316
0.006
0.016
0.037
0.042
0.054
Fat
Vitamin C
Fruits
Fruits + Vegetables
Vegetables
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Table 3. Cont.
Metabolite/ID Identifier T2 a F-test b p-value b r c p-value c Food Record d
Dihydroxybenzoic
acid
(DHBA) *
HMDB0001856
153.019:1.576 (−)
MSI-CE-MS
C7H6O4
Level 2
8.0 7.3 0.010
−0.403
0.383
0.355
0.324
0.310
0.012
0.018
0.029
0.047
0.058
Fat
Sugar % energy
Vitamin C
Vegetables
Fruits + Vegetables
Dimethylglycine
(DMG)
HMDB0000092
104.108:0.569 (+)
MSI-CE-MS
C4H9NO2
Level 1
2.9 3.6 0.065 0.3560.322
0.028
0.049
Fruits + Vegetables
Fiber (total)
a Hotelling’s T-squared distribution using MEBA on glog-transformed metabolomic time series data. b Mixed ANOVA model derived from within-subject (diet × time interaction, p < 0.05)
contrasts when adjusted for sex, age, and BMI. c Partial Pearson correlation of urinary metabolites to food records with listwise deletion when adjusted for sex, age, and BMI, where r > ±
0.30 and p < 0.05. d Top 5 nutrient categories from self-reported food records that were significantly correlated to urinary metabolites following contrasting provisional diets. * Exact
stereochemistry for tentatively identified metabolites (level 2) in urine was uncertain given other potential isomers.
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inaccurate self-reporting. Figure 4 illustrates metabolic trajectory plots for ProBet and Me-His as they 
were among the most sensitive biomarkers responsive to contrasting diets, and they were also 
measured consistently in both plasma and urine samples. Scatter plots show the quantitative 
relationship between Me-His and ProBet concentrations in plasma as compared to their excreted 
concentrations in urine with the self-reported average daily intake of protein (%energy), and fruit 
servings (servings/2000 kcal), respectively. For example, there was a 2.4-fold increase in mean plasma 
Me-His concentration following two weeks of food provisions that corresponded to a 28% greater 
intake of dietary protein when comparing Prudent (W-P, n = 24) and Western (P-W, n = 18) diet 
groups. Similar results were also evident when comparing creatinine-normalized concentrations of 
Me-His in urine, which generated a 4.8-fold higher mean concentration in the Prudent relative to 
Western diet treatment arm. Overall, there was a strong correlation between Me-His concentrations 
and self-reported dietary protein intake (r = 0.430 to 0.560) with few exceptions, such as one 
participant (W-P, #19) who had consistently low Me-His concentrations in both biofluids consistent 
with their self-reported protein intake that was characteristic of the Western diet group (P-W); this 
outcome likely indicates non-adherence to their assigned diet. In contrast, a second participant (P-W, 
#28) had higher Me-His concentrations in both plasma and urine despite their low self-reported 
protein intake from diet records that was suggestive of a reporting bias.  
Figure 4 also depicts metabolic trajectories for plasma and urinary ProBet concentrations after 
two weeks of food provisions as compared to their baseline habitual diet along with scatter plots 
depicting their correlation (r = 0.430 to 0.530) to daily fruit servings. Similar to Me-His, the same 
participant (W-P, #19) had lower ProBet concentrations in both plasma and urine with diet records 
reflecting a Western diet low in fresh fruit intake despite being assigned to the Prudent diet treatment 
arm. Additionally, three participants had higher than expected plasma ProBet status (P-W, #28, 35, 
36) inconsistent with self-reported diet records; interestingly, ProBet concentrations for window 
when analyzing complementary biofluids for exogenous dietary biomarkers of recent food intake. 
Overall, there was a strong positive correlation between Me-His (r = 0.638) and ProBet (r = 0.547) 
concentrations measured from matching plasma and urine samples (Figure S13) collected at baseline 
and following assigned diets (n = 84). Additionally, 2D heat maps and correlation matrices for top-
ranked plasma (14) and urinary (11) metabolites provide insights into their underlying biochemical 
relationships, or common dietary sources (Figure S14). As expected, urinary imidazole metabolites 
derived from histidine, Me-His and ImPA (r = 0.956), plasma saturated fatty acids, C14:0 and C15:0 
(r = 0.873), plasma branched-chain amino acid intermediates, kLeu and kVal (r = 0.705), as well as 
biotransformed plant-derived phenol metabolites in urine, DHBA and ETL-G (r = 0.662) were among 
a group of highly co-linear metabolites correlated to similar nutrient categories from self-reported 
diet records (Table 2; Table 3). 
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Figure 4. Metabolic trajectories for two dietary biomarkers in plasma and urine that increased 
following a Prudent diet (W-P) as compared to a Western diet (P-W), namely (A, B) Me-His and (C, 
D) ProBet. Both metabolites were not different at baseline, but undergo significant changes after two 
weeks of assigned food provisions (q < 0.05, FDR) with concentrations moderately correlated (r > 
0.400) to self-reported diet records, such as a higher average daily intake of fruit (ProBet) and protein 
(Me-His). Good dietary adherence was demonstrated for most DIGEST participants with only a few 
exceptions (labeled on plots), who had metabolic phenotypes inconsistent with their assigned diets 
following two weeks of food provisions. 
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Figure 4. Metabolic trajectories for two dietary biomarkers in plasma and urine that increased following
a Prudent diet (W-P) as compared to a Western diet (P-W), namely (A,B) Me-His and (C,D) ProBet.
Both metabolites were not different at baseline, but undergo significant changes after two eeks of
assign d f od provisions (q < 0.05, FDR) with concentrations moderately correlated (r > 0.400) to
self-reported diet recor s, such as a hig er verage daily int ke of fruit (ProBet) and protein (Me-His).
Good dietary adherence was demonstrated for most DIGEST participants with only a few exceptions
(labeled on plots), who had metabolic phenotypes inconsistent with their assigned diets following two
weeks of food provisions.
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Figure 4 also depicts metabolic trajectories for plasma and urinary ProBet concentrations after two
weeks of food provisions as compared to their baseline habitual diet along with scatter plots depicting their
correlation (r = 0.430 to 0.530) to daily fruit servings. Similar to Me-His, the same participant (W-P, #19) had
lower ProBet concentrations in both plasma and urine with diet records reflecting a Western diet low in
fresh fruit intake despite being assigned to the Prudent diet treatment arm. Additionally, three participants
had higher than expected plasma ProBet status (P-W, #28, 35, 36) inconsistent with self-reported diet
records; interestingly, ProBet concentrations for window when analyzing complementary biofluids for
exogenous dietary biomarkers of recent food intake. Overall, there was a strong positive correlation
between Me-His (r = 0.638) and ProBet (r = 0.547) concentrations measured from matching plasma and
urine samples (Figure S13) collected at baseline and following assigned diets (n = 84). Additionally, 2D heat
maps and correlation matrices for top-ranked plasma (14) and urinary (11) metabolites provide insights
into their underlying biochemical relationships, or common dietary sources (Figure S14). As expected,
urinary imidazole metabolites derived from histidine, Me-His and ImPA (r = 0.956), plasma saturated
fatty acids, C14:0 and C15:0 (r = 0.873), plasma branched-chain amino acid intermediates, kLeu and
kVal (r = 0.705), as well as biotransformed plant-derived phenol metabolites in urine, DHBA and ETL-G
(r = 0.662) were among a group of highly co-linear metabolites correlated to similar nutrient categories
from self-reported diet records (Table 2; Table 3).
4. Discussion
4.1. Contrasting Diets from Food Provisions
Accurate assessment tools of complex dietary patterns are needed to promote human health since
sub-optimal diets are responsible for about 20% of preventable deaths from non-communicable diseases
worldwide [43]. However, few validated biomarkers exist for routine monitoring of habitual diet [44],
such as omega-3 fatty acids [45] and water-insoluble fiber [46]. In this work, a panel of metabolites
from plasma and urine was demonstrated to respond to short-term dietary changes when applying a
cross-platform metabolomics approach with stringent QC (Figure 1; Figure S2), and a rigorous data
workflow for metabolite authentication (Figure 2; Figure S3) [30–32]. Since DIGEST participants had
poor Prudent diet eating habits, and only modest differences associated with their aggregate Western
diet scores (p = 0.0037) at baseline (Table S1), we hypothesized that assigning a Prudent diet (W-P) from
food provisions would likely induce a more pronounced metabolic phenotype change than a Western
diet (P-W); indeed, several top-ranked metabolites (q < 0.05, FDR) measured in plasma and urine
were largely associated with a Prudent diet as shown in volcano plots (Figure S5). Unlike controlled
feeding studies within a laboratory setting, DIGEST participants were provided cooking suggestions
with meal plans by a dietician that still allowed for flexibility in food preparations [25]. In this
study, short-term dietary changes were found to impact the intake of 20 specific nutrient categories
from self-reported diet records (Table 1; Figure S4). For instance, a Prudent diet was consistent with
higher consumption of dietary fiber, fruits and/or vegetables, electrolytes and vitamins, but with
lower intake of dietary fat, sodium and cholesterol in contrast to a Western diet. To the best of our
knowledge, this is the first metabolomics study to investigate the impact of contrasting diets using
food provisions. As dietary adherence, potential misreporting, and variations in food preparations
represent uncontrolled variables in this study, we aimed to identify metabolites from plasma and urine
that can serve as robust biomarkers of changes in habitual diet applicable to a free-living population.
4.2. Robust Biomarkers of a Prudent Diet Measured in Both Plasma and Urine
ProBet (Figure 2) and Me-His (Figure S6) were among the most significant metabolites (q < 0.05,
FDR) associated with a Prudent diet, an eating pattern that promotes good health while contributing
to chronic disease prevention [47,48]. In this case, ProBet and Me-His displayed opposing metabolic
trajectories in both plasma and urine after two weeks of a Prudent or Western diet with no differences
measured at baseline (Figure 4). This was a consistent outcome from univariate (Figure S5)
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and multivariate (Figure 3) statistical methods after adjustments for covariates (sex, age, BMI),
including mixed ANOVA and correlation models (Table 2; Table 3). Indeed, plasma ProBet or the ratio
of Me-His/C18:3n-6cis provided good discrimination (AUC ≈ 0.82 to 0.87, p < 3.0 × 10−5) of contrasting
dietary patterns (Figure S10). Additionally, ProBet and Me-His concentrations in plasma and urine
were positively associated (r ≈ 0.40–0.60, p < 0.001) with eating patterns reflecting a Prudent diet,
including a higher daily intake of total fiber, fruits and/or vegetables, protein, vitamins, and electrolytes,
along with a lower consumption of trans or saturated fats as compared to a Western diet. In fact,
ProBet is an exogenous biomarker specific to citrus fruit that has been validated in well-controlled
feeding studies [49] since it is not prevalent in most other foods [50]. In fact, ProBet has been
replicated in large-scale observational studies as a robust dietary biomarker (r ≈ 0.40) of recent citrus
fruit/juice intake when compared to standardized FFQ, which can be measured in either blood or urine
specimens [18].
Me-His has long been reported as an index of myofibrillar muscle protein turn-over under
fasting conditions [51], whereas it also can serve as a biomarker of recent meat consumption
(e.g., chicken) with lower plasma concentrations measured in vegetarians as compared to omnivores [52].
Consequently, fasting plasma and creatinine-normalized urinary concentrations of ProBet and Me-His
were associated with average daily intake of fruit (servings/2000 kcal) and protein (%energy) as the
most likely primary food sources (Figure 4), respectively, which also confirmed good dietary adherence
among DIGEST participants with only a few exceptions. For instance, one participant following a
Prudent diet (#19, W-P) had consistently lower than expected concentrations of ProBet and Me-His
in both plasma and urine samples, which correctly corresponded to their self-reported diet records.
In contrast, three participants following a Western diet (#25, 36, 38, P-W) were found to have higher
than expected plasma ProBet when compared to their diet record, but this trend was less apparent
in their matching urine samples. These observations are likely due to incidental intake of fruit juice
or citrus beverages not included with food provisions, which also highlights the different detection
windows for dietary biomarkers when relying on a single-spot plasma, and random urine sample
in this study [16]. For instance, ingestion of ProBet or orange juice results in a peak concentration
in circulation (<1–2 h) that reflects more recent intake as compared to its later excretion in urine
(<2–24 h) [53]. Nevertheless, there was a strong linear correlation between circulating and excretory
concentrations of ProBet (r = 0.638) and Me-His (r = 0.547) measured in matching plasma and urine
samples collected in this study (Figure S13).
4.3. Novel Biomarkers Identified Following a Prudent Diet
Two urinary metabolites were also identified by MS/MS (level 2, Figure S7) as sensitive
dietary biomarkers (q < 0.05, FDR) reflecting a Prudent diet, namely OH-PCA and ImPA (Table 3).
Other potential isomeric/isobaric candidates for these metabolites were ruled out by comparing their
MS/MS spectra with those predicted in silico using CFM-ID [37] in the absence of authentic standards
for more confident identification (level 1). Their metabolic trajectories (Figure S12) displayed a notable
increase (FC ≈ 4 to 6, p < 0.001) in excretion following a Prudent diet with no differences measured at
baseline similar to trends for urinary ProBet and Me-His excretion. ImPA is a normal constituent of
human urine derived from the metabolism of histidine [54], which has recently been identified as a
product of gut microbiota activity that also regulates insulin sensitivity [55]. This highlights the fact
that many dietary biomarkers are not only dependent the intake of foods and host (liver) metabolism,
but are also co-metabolized by intestinal microbiota with poorly understood effects on human health.
Urinary excretion of ImPA was significantly correlated with fiber, fruits and/or vegetables, and protein
intake (r ≈ 0.50, p ≈ 0.001), which comprise eating patterns consistent with a Prudent diet [47].
Similarly, urinary OH-PCA was found to have a moderate correlation with daily intake of total
fiber, fruits and/or vegetables, which was also inversely related to total fat. This data indicates that
higher excretion of OH-PCA in urine is likely derived from intake of leguminous plants [56], and/or
citrus fruits [57] when following a Prudent diet even though it also represents an endogenous lysine
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metabolite [58] produced by commensal gut microbiota [59]. Indeed, urinary OH-PCA or its ratio
to sodium (OH-PCA/Na+) discriminated between DIGEST participants from the two diet treatment
arms (Figure S10) with good accuracy (AUC ≈ 0.83 to 0.88, p < 3.0 × 10−4), as well as sensitivity and
specificity (≈ 90%).
Two other metabolites derived from edible plant sources were also identified by MS/MS (Figure S8)
since they were elevated in urine (FC ≈ 2.5 to 3.8) following a Prudent diet as shown by their
urinary metabolic trajectory plots (Figure S12), namely ETL-G and DHBA. In the case for ETL-G,
a MS/MS spectral match based on three characteristic product ions, including a neutral mass loss
corresponding to a glucuronic acid (m/z 176.032) that is in close agreement with published data [60].
These urinary metabolites were consistently associated (r ≈ 0.30-0.40, p < 0.05) with fruits, vegetables,
vitamin C, and/or total sugar intake, and inversely correlated to total fat (Table 3). ETL-G is a major
phytoestrogen from dietary plant lignins, and is excreted in urine as its monoglucuronide conjugate
following biotransformation by human intestinal bacteria [61]. Even in controlled feeding studies,
there is considerable between-subject variation in the urinary excretion of enterolignin metabolites
due to complex interactions with liver and colonic environments [62], which has been reported to
possess putative anticancer, antioxidant and/or estrogenic activity [63]. DHBA is a major phenolic acid
constituent from most cereals (e.g., wheat, rye) [64], which can serve as a biomarker of dietary fiber
intake allowing for differentiation of contrasting low and high (> 48 g/day) fiber diets [65]. In fact,
urinary DHBA was the only biomarker differentially excreted at baseline, which likely reflected modest
differences in fiber intake (p = 0.018, Table S1) between DIGEST participant sub-groups (Figure S5).
Urinary Val-Val and DMG were also biomarkers related to a Prudent diet, but had weak correlations
with only two nutrients (Table 3), whereas the artificial/low calorie sweetener ASK, and inorganic nitrate
were not associated with any nutrients from self-reported diet records (Figure 3). ASK was elevated
following a Western diet (Figure 3B), but was rather sporadic with frequent missing data (i.e., below
detection limit) since it reflects recent intake of certain sugar-sweetened beverages [66]. In contrast,
nitrate exposure has been reported to be mainly from vegetable consumption due to agricultural
fertilizer usage [67] that is consistent with its greater excretion in urine following a Prudent diet.
The major circulating ketone body, OH-BA and two branched-chain amino acid intermediates,
kVal and kLeu also increased in plasma following a Prudent diet as compared to a Western diet
(Table 2). Increases in OH-BA from the liver during ketosis occurs during prolonged fasting or
following strenuous exercise [32], as well as abrupt changes in habitual diet, such as adopting a low
glycemic index or very low carbohydrate diet [19]. In our work, plasma OH-BA was moderately
correlated (r ≈ 0.42, p < 0.01) to increases in daily intake of fruits and/or vegetables, and poly:sat, as
well as being inversely associated with saturated and trans fat consumption. Since a Prudent diet is
characterized by greater consumption of fiber-rich foods having a lower glycemic index, this may
contribute to a mild ketogenic physiological state unlike a Western diet that is characterized by
regular consumption of processed foods high in salt and added refined sugar, but low in dietary
fiber [47,48]. Indeed, a Prudent diet composed of whole foods elicits fewer adverse health effects
with better adherence than highly restrictive ketogenic diets, which has been shown to be effective
in regulating insulin sensitivity in type 2 diabetes and pre-diabetic patients [68]. Plasma kVal and
kLeu were also positively correlated (r ≈ 0.45-0.50, p < 0.004) with key nutrients associated with a
Prudent diet, including greater daily intake of protein, fruits and/or vegetables, poly:sat, and vitamins.
Both plasma metabolites are generated by extra-hepatic branched-chain amino acid transferases prior
to oxidative decarboxylation and subsequent utilization as energy substrates within muscle tissue [69].
The metabolism of branched-chain amino acids plays other critical roles in human health, including
ammonia detoxification, protein biosynthesis and insulin sensitivity [70] while serving as predictive
biomarkers of type 2 diabetes [71]. A correlation matrix/heat map (Figure S14) confirms that plasma
kLeu and kVal were strongly co-linear (r ≈ 0.70, p = 6.8 × 10−14) while also being closely associated with
OH-BA (r ≈ 0.48, p = 3.7 × 10−6) reflecting common dietary patterns that influence their circulating
concentrations. Also, urinary Me-His and ImPA (r ≈ 0.96, p < 1.0 × 10−15), as well as plasma C14:0 and
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C15:0 (r ≈ 0.87, p = 8.4 × 10−15) were among the most strongly correlated metabolites that are derived
from consumption of foods rich in dietary histidine and saturated fats, respectively.
4.4. Novel Biomarkers Identified Following a Western Diet
Unlike branched-chain amino acid intermediates, two circulating amino acids, Ala and Pro were
associated with greater daily intake of dietary fats (saturated, trans, total), and inversely correlated
to a Prudent diet due to lower consumption of fruits, vegetables, and protein (Table 2). As a result,
their plasma metabolic trajectories increased when DIGEST participants were assigned a Western
diet after two weeks (Figure S11). Fasting amino acid concentrations reflect long-term habitual diet
rather than recent dietary intake, where Ala has been reported to be inversely associated to plant-based
protein diets [72]. This is consistent with outcomes in our study, since plasma Ala was negatively
correlated to average daily protein intake (r ≈ −0.40, p = 0.014). Similar to Ala, plasma Pro was reported
to be inversely associated with a Prudent diet as measured in a cross-sectional observational study
that was adjusted for age, sex, and BMI [73]. This was consistent with our findings since plasma
Pro was inversely related to healthy eating patterns, such as lower intake of fruits and/or vegetables,
and higher consumption of processed foods with trans fats (Table 2). As expected, plasma Pro was
correlated (r ≈ 0.46–0.49, p < 1.0 × 10−5) with circulating levels of Ala, as well as C0 that was indicative
of a Western diet (Figure S14). Similar outcomes were also measured for two carnitine metabolites
(C0 and dC0) since they had metabolic trajectories that increased for DIGEST participants following
a Western diet, which were correlated with greater intake of dietary fat, sodium, and cholesterol
(Table 2). Although de novo synthesis of C0 is derived from dC0 via lysine metabolism, red meat
represents a major dietary source of C0 that is also metabolized by gut microbiota with subsequent
host hepatic conversion to generate the thrombosis-promoting metabolite, N-trimethylamine oxide
(TMAO) [74]; however, plasma or urinary TMAO were not found to be modulated by short-term
contrasting diets in our study. In fact, recent studies have shown that anaerobic gut microbiota species
can also generate TMAO via its atherogenic intermediate, dC0 due to chronic C0 exposure from the
diet [75]. Nevertheless, C0 is still widely promoted as a nutritional supplement and ergogenic aide to
improve fatty acid energy metabolism, as well as alleviate muscle injury from strenuous exercise [76].
Lastly, a series of plasma total (hydrolyzed) fatty acids had metabolic trajectories that increased when
following a Western diet, which were directly associated with greater intake of total, saturated and
trans fats, and a lower consumption of poly:sat, vitamins, and fruits and/or vegetables (Table 2).
For example, a low abundance circulating trans fatty acid, C18:2n-6trans, as well as saturated fats (C14:0,
C15:0), and omega-6 fatty acids, namely C18:3n-6cis and C18:2n-6cis were among the most significant
plasma FA that increased following two weeks of a Western diet. Indeed, high intake of omega-6 [77]
and saturated [78] fatty acids has long been associated with a Western diet that increases systemic
inflammation and chronic disease risk. Nevertheless, there remains on-going controversy regarding the
optimal dietary fat composition needed to promote cardiometabolic health [79]. Recent clinical trials
and observational studies have demonstrated that circulating C14:0, C17:0 and notably C15:0 represent
dietary biomarkers of dairy fat intake whose impact on human health may likely be beneficial [80].
In contrast, a greater consumption of processed foods containing vegetable oils rich in C18:2n-6cis,
and other omega-6 fatty acids is likely a major dietary culprit for CVD prevalence in developed
countries [81]. Public health policies have been far more effective in the past decade to reduce dietary
trans fat intake to less than 1% energy based on WHO recommendations with animal meats/dairy
now being more significant than industrial sources from partial hydrogenation of vegetable oils [82].
These trends are consistent with data measured in our work, as fasting plasma concentrations of
C18:2n-6trans were about 0.34% of its stereoisomer and most abundant FA in circulation, C18:2n-6cis
(Figure S9).
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5. Conclusions
In summary, a panel of dietary biomarkers that reflect contrasting Prudent and Western diets
were identified based on their distinctive metabolic trajectories measured in paired plasma and urine
samples using a cross-platform metabolomics strategy. All DIGEST participants were provided
foods for consumption over a two week period while maintaining normal lifestyle habits with no
significant changes in their caloric intake, BMI, blood pressure, as well as standard lipid or inflammatory
biomarkers as compared to baseline. Me-His and ProBet were the most significant dietary biomarkers
associated with a Prudent diet consistently measured in both plasma and urine. Also, urinary
ImPA, OH-PCA, ETL-G and DHBA, as well as fasting plasma OH-BA, kVal and kLeu were also
positively associated with a Prudent diet. These dietary biomarkers reflect greater consumption of
health-promoting foods containing insoluble fiber, protein, essential vitamins/electrolytes, and bioactive
phytochemicals with a low glycemic index as compared to highly processed foods in contemporary
Western diets. Also, a series of circulating saturated and polyunsaturated fatty acids, as well as plasma
Ala, Pro, C0 and dC0 were classified as dietary biomarkers of a Western diet reflecting greater intake of
fats, cholesterol and salt, but having lower overall nutrient and fiber quality. Other urinary biomarkers
of contrasting diets included ASK, nitrate, DMG and Val-Val, but they did not have strong associations
with any specific nutrient categories from self-reported food records. Urine offers a less invasive and
more convenient biofluid than blood with a wider detection window for tracking dietary biomarkers
in observational studies; however it is more variable when relying on random/single-spot samples due
to between-subject differences in hydration status that require normalization. Strengths of this study
include the use of complementary statistical methods with appropriate adjustments, access to matching
biospecimens and food records from participants, and implementation of a validated metabolomics
data workflow for biomarker discovery and authentication with stringent QC. However, there were
several study limitations, including the short duration of the dietary intervention, as well as modest
sample size involving participants recruited from a single center without strict dietary adherence
monitoring, or recording of food preparation methods. Future studies that include multiple time points
for biomonitoring of long-term changes in habitual diet with greater study power are recommended.
Also, the integration of metabolomics with fecal microbiome data is needed given the important roles
of commensal gut microbiota in nutrient generation, and metabolite biotransformation that varies
between participants. Also, certain dietary biomarkers tentatively identified in this study require
further structural elucidation to confirm their exact stereoisomer configuration. The advent of high
throughput and low cost metabolomics technologies allows for a more accurate assessment of diet
exposures applicable to large-scale epidemiological and clinical intervention studies. This is urgently
needed to validate the utility of dietary biomarkers in nutritional epidemiology to better guide public
health policies for the prevention of cardiometabolic and neurodegenerative disorders that increasingly
impact an aging population. Overall, our results provide strong corroborating evidence of the utility
of food exposure biomarkers to accurately differentiate complex dietary patterns in a free-living
population outside a laboratory setting. Future metabolomic studies will focus on assessing maternal
nutrition during critical stages of fetal development, and its impact on obesity and metabolic syndrome
risk in childhood later in life.
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